EMERYVILLE, Calif. — Kyverna Therapeutics, Inc. (Kyverna), a patient-centered, clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced the signature of a collaboration agreement with Stanford University to allow the use of KYV-101, an investigational, anti-CD19 CAR T-cell therapy in an open label,...
Latest News
EMERYVILLE, Calif. — Kyverna Therapeutics, Inc., a patient-centered clinical-stage biopharmaceutical company focused on developing cell therapies for patients suffering from autoimmune diseases, today announced it received fast track designation by the U.S. Food and Drug Administration (FDA) for its autologous, fully human CD19 chimeric antigen receptor (CAR) T-cell product candidate,...
LA JOLLA, CA — La Jolla Institute for Immunology (LJI) is working to guide the development of new tuberculosis vaccines and drug therapies. Now a team of LJI scientists has uncovered important clues to how human T cells combat Mycobacterium tuberculosis, the bacterium that causes TB. Their findings were published...
BURLINGTON, N.C. – Labcorp® (NYSE: LH), a leading global life sciences company, today announced the availability of therascreen® KRAS PCR Mutation Analysis, a companion diagnostic to identify patients with non-small cell lung cancer (NSCLC) who are eligible for treatment with LUMAKRAS™ (sotorasib), a new treatment option developed by Amgen. Labcorp’s...
BURLINGTON, N.C. — Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch and availability of a new, FDA-cleared blood test for risk assessment and clinical management of severe preeclampsia, a life-threatening blood pressure disorder that occurs during pregnancy and the postpartum period. Preeclampsia...
BURLINGTON, N.C. — LabCorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the U.S. Food and Drug Administration (FDA) has approved its nAbCyte™ Anti-AAVRh74var HB-FE Assay, a companion diagnostic (CDx) to determine patient eligibility for treatment with BEQVEZ™ (fidanacogene elaparvovec-dzkt), Pfizer’s recently FDA-approved hemophilia B gene therapy. The...
SHANGHAI and WARREN, N.J. — Laekna, a clinical-stage biotechnology company, today announced that the company will present a novel therapeutical approach to treat liver fibrosis in the form of a poster at the NASH-TAG conference from January 4-6, 2024, in Park City, Utah. The presentation will showcase a novel antibody-based...
Reporthive.com introduced key new research reports encompassing the Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics market. The aim of the study is to provide market leaders with a revolutionary decision-making tool that covers key fundamentals of the Lambert-Eaton Myasthenic Syndrome (LEMS) Therapeutics market. The Report Covers Market Size, Share, product Segmentation, CAGR,...
HAIFA, Israel — MAGENTIQ EYE LTD., an Israeli based technology company founded in 2014, announced today that a comprehensive study on the performance of MAGENTIQ-COLO™ CADe version has been published in the prestigious Lancet Digital Health medical journal. The study, titled “A novel computer-aided polyp detection system in screening and...
The suspicion that something was wrong started when the 1-year-old girl’s parents noticed she had trouble holding up her head. It was just the first of what would be many missed developmental milestones. By the time she was 8, the little girl still couldn’t sit up on her own, hold...